Category: ACN Newswire

SHENZHEN, CHINA, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 2 December 2024, the Group through a wholly-owned subsidiary of the Company entered into an Exclusive Commercialization Agreement (the “Agreement”) with Atom Therapeutics Co., Ltd (hereinafter referred to as “Atom Therapeutics”, formerly named as “Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.”) of class 1 innovative drug ABP-671 for the treatment of gout and hyperuricemia (the “Product”). In accordance with the Agreement, the Group is entitled to an exclusive commercialization right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The term of cooperation commences on the effective date of the Agreement and extends for ten years from the date the Product is first approved for market launch in Mainland China (the "Authorization Term"). Upon the expiration of the Authorization Term, it may be automatically renewed for an additional ten years, subject to specific conditions stipulated in the Agreement.ABP-671 is a class 1 innovative chemotherapeutic drug for the treatment of gout and hyperuricemia, currently in Phase 2b/3 clinical trials for gout in China and overseas. The Product reduces renal re-absorption of uric acid by inhibiting Urate Anion Transporter 1 (URAT1). The results of two completed phase 2 clinical trials demonstrated favorable efficacy and safety profiles across multiple dose groups (ranging from 1 mg to 12 mg) of ABP-671. The 2 mg once-daily dosage of the Product was proved to be as effective as, or even better than, benzbromarone or febuxostat (maximum dosage of 80mg). The reduction in uric acid levels was sustained throughout the 24-hour period, with no significant safety concerns identified. This product is anticipated to offer more effective and safer treatment alternatives for patients suffering from gout and hyperuricemia[1]. Multiple patents in regard to substance and use of the ABP-671 have been granted in China.Hyperuricemia is defined as a fasting blood uric acid level exceeding 420μmol/L (7.0 mg/dL) in adults on a normal purine diet on two separate days. The deposition of urate crystals in hyperuricemia patient results in arthritis, medically termed gout. Hyperuricemia and gout can cause acute and chronic inflammatory injury in articular cartilage, bone, kidney and vascular wall, which can lead to multiple organ damage of the heart, brain and kidney, etc. The data presented in the White Paper on Hyperuric Acid and Gout Trends in China (2021) indicates that, the incidence rate of hyperuricemia is 13.3%, with approximately 177 million hyperuricemia patients and the incidence rate of gout is 1.1% in general, with about 14.66 million gout patients in China. Frost & Sullivan indicates that, the number of people with hyperuricemia and gout in China will continue to increase in the future, reaching 240 million and 52.2 million respectively by 2030. Currently, the commonly used uric acid-lowering drugs in clinical practice in China are those which inhibit uric acid synthesis or promote uric acid excretion. Due to certain limitations in the efficacy and safety of the marketed uric acid-lowering drugs, such as causing renal failure, sudden cardiac death or severe liver toxicity. There is still an urgent need for effective and safe uric acid-lowering drugs among gout and hyperuricemia patients in China.ABP-671 is currently with the potential to be the promising and safe product for the treatment of gout and hyperuricemia. Through this collaboration, it fills the blank in the CMS's product portfolio of the treatment of gout. Gout and hyperuricemia are both rheumatic diseases and chronic metabolic diseases, which are highly consistent with the Group's strategic layout in the cardio-cerebrovascular/ gastroenterology business and the network resources of marketed products. If approved for marketing in the future, the Product will synergize with the Group’s marketed product Metoject (methotrexate injection) in rheumatology and with Elcitonin (elcatonin injection) in endocrinology and orthopedics, in terms of expert network and market resources. Based on the unmet clinical needs and the expected solid clinical data of the Product, the Group is looking forward to the smooth advancement of the clinical development of ABP-671, allowing patients with relevant indications to benefit from this innovative treatment sooner.About ATOM THERAPEUTICSAtom Therapeutics was founded in March 2012, focused on the research and development of innovative drugs with global commercial value and competitiveness in the metabolic and inflammatory area. Atom Therapeutics's main core team members come from the United States, with extensive experience in the research and development of innovative drugs. Atom Therapeutics has achieved remarkable development in the past few years. Atom Therapeutics's core product ABP-671 is under pivotal clinical stage for the treatment of chronic gout. Atom Therapeutics's another small molecule innovative drug named as ABP-745, used for indications in the field of anti-inflammatory immune indications. The Phase 1 clinical of ABP-745 exhibited outstanding pharmacokinetics and safety. The clinical trial is on the verge of entering Phase 2. For more information about Atom Therapeutics and its pipeline, please visit https://www.atombp.com/.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.Reference:1. The results of Phase 2 clinical trials was published and can be found at: https://www.atombp.com/2023/03/01/atom-bioscience-announces-positive-results-of-phase-2a-china-clinical-trial-of-its-urat1-inhibitor-for-chronic-gout/CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.

SHANGHAI, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everest’s New Drug Application (NDA) for VELSIPITY(R) (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis. VELSIPITY(R) is an effective and convenient, once-daily, oral treatment for patients with moderately-to-severely active UC that has already been approved in the U.S. and E.U., and other countries, by Everest’s licensing partner, Pfizer. In Everest territories, the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China has approved the NDA for VELSIPITY(R) in April of this year and was implemented in the Guangdong-Hong Kong-Macau Greater Bay Area this October through the "Hong Kong and Macau Medicine and Equipment Connect" policy."Autoimmune disease is a core focus and a significant growth driver for our company. The number of UC patients in China is projected to double from 2019 to 2030 to approximately one million, highlighting the urgent need for novel treatments." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Previously, VELSIPITY(R) has already been approved in Macau, China, and was implemented in the Greater Bay Area through the connect policy. The company also plans to submit the NDA for approval by China’s National Medical Products Administration (NMPA) this year, with the aim of benefiting more Chinese patients as soon as possible."" This is an important advancement for etrasimod, bringing hope to patients in Hong Kong, China. This new-generation S1P receptor modulator is an oral, once-daily treatment that can provide patients with a chance for corticosteroid-free remission, mucosal healing, and rapid symptom relief, " said Prof. Wu Kaichun with the First Affiliated Hospital of AFMU who is the principal investigator for etrasimod’s Asia clinical trial. “We hope China and other Asian countries can obtain approvals as soon as possible to benefit more patients."The acceptance of the NDA was based on results from the ELEVATE UC Phase 3 registrational program (ELEVATE UC 52 and ELEVATE UC 12) that evaluated the safety and efficacy of etrasimod 2 mg once-daily on clinical remission in UC patients with moderately to severely active UC who had previously failed or were intolerant to at least one conventional, biologic, or Janus kinase (JAK) inhibitor therapy. Nearly two-thirds of patients in ELEVATE UC 52 and ELEVATE UC 12 were naïve to biologic or JAK inhibitor therapy, and these studies were also the only studies for advanced therapies for ulcerative colitis to include patients with isolated proctitis. Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of etrasimod.Everest conducted a multicenter, randomized, double-blind and placebo-controlled Phase 3 trial of etrasimod in Asian countries, including mainland China, China Taiwan and South Korea. This is the largest Phase 3 trial of moderately-to-severely active ulcerative colitis in Asia completed to date, with 340 eligible subjects randomized to treatment with etrasimod or placebo. The previously announced results of the induction period indicate that the clinical remission rate for patients treated with etrasimod 2mg was 25.0%, compared to 5.4% for those treated with placebo (difference 20.4%, p

上海, 2024年12月2日 - (亞太商訊 via SeaPRwire.com) -雲頂新耀（HKEX 1952.HK）是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈中國香港衛生署已正式受理伊曲莫德（VELSIPITY(R)）用於治療中重度活動性潰瘍性結腸炎成人患者的新藥上市許可申請（NDA）。伊曲莫德是一款每日一次口服的一線先進療法，不僅使用方便、療效佳，而且具有良好的安全性特征。伊曲莫德已於去年10月和今年2月先後在美國和歐盟獲得新藥上市批准，同時，伊曲莫德也於今年4月獲得中國澳門特別行政區藥物監督管理局批准上市，並於今年10月通過「港澳藥械通」政策在粵港澳大灣區落地。雲頂新耀首席執行官羅永慶表示：「我們非常高興看到伊曲莫德的新藥上市許可申請在中國香港獲得正式受理。自身免疫性疾病是我們的重點關注領域和重要價值的潛在增長動力。到2030年，中國的潰瘍性結腸炎患者人數預計將達到約100萬人，超過2019年患者人數的一倍以上，存在迫切且巨大的未被滿足的臨床需求。伊曲莫德已在中國澳門獲批，並通過「港澳藥械通」政策率先在粵港澳大灣區落地。今年我們預計也將在中國大陸地區遞交伊曲莫德的新藥上市許可申請。期待伊曲莫德在更多地區獲批，進一步擴大可及性，造福廣大患者。」伊曲莫德亞太臨床試驗牽頭研究者、世界胃腸病學會執行理事、亞太消化學會副主席、中國人民解放軍空軍軍醫大學附屬西京醫院吳開春教授表示：「祝賀伊曲莫德取得的這一新進展，為中國香港的患者帶來了希望。伊曲莫德具有良好的獲益-風險特征，這種新一代S1P受體調節劑通過每日一次口服的治療方案，可快速起效，並達到無激素緩解、黏膜癒合，可為中重度活動性潰瘍性結腸炎成人患者提供先進的治療選擇。我們期待伊曲莫德在大中華區及其他亞洲國家早日獲批，為患者帶來福音。」伊曲莫德的申請是基於ELEVATE UC III期註冊研究（ELEVATE UC 52和ELEVATE UC 12）的結果，該研究旨在評價既往對至少一種常規治療、生物製劑或Janus激酶（JAK）抑制劑治療失敗或不耐受的中重度活動性潰瘍性結腸炎患者，每日一次服用2mg 伊曲莫德的安全性和療效。在ELEVATE UC 52和ELEVATE UC 12中，納入了一半以上嚴重活動性潰瘍性結腸炎患者（mMS≥7），並有近三分之一患者曾接受過生物製劑或JAK抑制劑治療。伊曲莫德的UC研究也是迄今唯一納入了孤立性直腸炎患者的UC研究。這兩項隨機、雙盲、安慰劑對照研究均達到了所有主要和關鍵次要終點，安全性特征與既往研究一致。在ELEVATE UC 52研究中，第12周時，接受伊曲莫德治療的患者臨床緩解率為27.0%（安慰劑組7.0%, 差異20.0%，P

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - November 25, 2024) - Military Metals Corp. (CSE:MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI") has issued an invitation to tender bids for carrying out a mineral resource estimation at the Company's Trojarová antimony-gold property in Slovakia. Three companies with recognized technical credentials were selected to submit bids.Trojarová, located in the heart of Europe, had prior development and production operations in respect of antimony. Historical resource estimates were produced in connection with Soviet era work conducted on the property, in accordance with the Russian classification system at the time. Please refer to the Company's news release dated October 30, 2024 for more detailed information about this antimony-gold deposit and the prior estimates. The historical work conducted is instructive as to future work programs to be conducted by the Company.The Company expects to receive bids by December 20, 2024 and to make a decision by year's end as to which company it will commission with a three-fold task:Input all historical data into a digital data base, including drill logs and analyses, plans, section, underground geological mapping and sampling, historical block modeling and all other relevant data, in order to generate an independent three-dimensional model and seek to verify the accuracy of the historical estimates on the property:Make recommendations to management in regard to the number, location, orientation and depth of twin and infill holes to be drilled, along with all quality assurance, quality control protocols, in order that the non-compliant historical resource can be upgraded and classified as a mineral resource in accordance with current industry standards;On completion of the new drill program outlined in items 1 and 2 above, input all newly generated drill data and prepare a "maiden" mineral resource estimate.Management eagerly awaits receipt of bids and then plans to move forward with the above three step program. With continuation of high antimony prices and demand, management believes that conducting work on Trojarová can add significant value for shareholders.The technical contents of this release were reviewed and approved by Avrom E. Howard, MSc, PGeo, geological consultant to Military Metals and a qualified person as defined by NI 43-101.About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD of DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.comFor enquiries, please call 604-722-5381 or 604-537-7556This news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this news release includes statements related to the filing of a NI 43-101 compliant technical report, activities related to the classification of mineralization documented at Trojarova as a current mineral resource, work to be conducted by the successful bidding party for the work described in the news release, future drill programs and other exploration work, and any future plans for activities at Trojarova. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include, geopolitical developments related to the supply of antimony, the continued use of antimony and availability of alternatives, future prices of antimony, availability of capital and labour in respect of Trojarova, any required approvals related to exploration activities to be conducted, the completion of successful bids as part of the process outlined in the news release, the results of any future exploration activities, which cannot be guaranteed, and such other factors as may impact any future activities in respect of the properties held by the Company. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231241 Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年11月30日 - (亞太商訊 via SeaPRwire.com) - 華領醫藥（「公司」，香港聯交所股份代號：2552.HK）今天在第九屆中國醫藥創新與投資大會（The China BioMed Innovation and Investment Conference，以下簡稱CBIIC）上宣佈，已經成功完成在美國開展的第二代葡萄糖激酶激活劑（GKA）的Ia臨床研究。第二代GKA（HM-002-1005）Ia臨床試驗是在美國40例2型糖尿病（T2D）受試者中進行的隨機、雙盲安慰劑對照、單劑量、安全性、耐受性、藥代動力學研究。第二代GKA是一種具有優化的理化性質的新分子實體，擁有新專利，為多格列艾汀（HMS5552）前藥。該項研究設計為每日一次口服給藥，旨在通過緩釋技術來延長藥物在體內的作用時間、改善患者依從性以及延長刺激腸道內GLP-1分泌的效果。這一單次劑量遞增（SAD）研究結果顯示，HM-002-1005片在人體內可迅速轉化為HMS5552，前藥在血漿和尿液中的暴露量極低。HM-002-1005片單次給藥後的t1/2（生物半衰期）相較於多格列艾汀片延長。184.5mg單次給藥後，血漿中HMS5552的Cmax與多格列艾汀片75mg單次給藥後的血漿HMS5552濃度相當；同時，血漿中HMS5552的單日AUC與多格列艾汀片75mg一天兩次給藥後HMS5552的暴露水平相當。該研究表明，HM-002-1005片在人體內幾乎完全轉化為HMS5552，且其藥代動力學特徵支持每日一次口服給藥方式。HM-002-1005片的開發不僅有利於提高患者服藥的依從性，實現24小時內有效控制血糖；同時，也為探索每日150mg以上的最大耐受劑量提供了機會，以獲得更好的治療效果。多格列艾汀75mg每日兩次（BID）劑量是根據最低有效治療劑量的治療理念，針對中國2型糖尿病患者普遍存在的胰島素分泌缺陷和早相胰島素分泌顯著降低而開發的劑型。西方2型糖尿病患者具有不同的疾病特點，往往合併肥胖症狀，多格列艾汀能夠促進GLP-1分泌、改善胰島素敏感性，有望為該患者群體帶來新的獲益。該研究結果確認HM-002-1005片184.5mg的暴露水平與多格列艾汀片75mg BID相當，公司將進一步優化劑型，在中國和美國進行第二代GKA的多次遞增劑量（MAD）臨床開發。華領醫藥創始人、CEO陳力博士表示：「華領醫藥始終致力於通過修復患者血糖自主調控能力，從源頭上治療2型糖尿病。公司歷經十年，選擇了針對大多數中國糖尿病患者安全有效的用藥劑量方案和臨床研究方案，實現了GKA的成功開發和多格列艾汀的臨床應用。在此基礎上，公司將進行戰略升級，通過繼續探索GKA的用藥潛力、豐富產品管線，在國內外尋求合作夥伴，惠及更多患者人群、拓展全球市場，更好地實現GKA藥物的品牌建設和全球首創新藥的商業價值。」關於華領華領醫藥（「本公司」）是一家總部位於中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥匯聚全球醫藥行業高素質人才，融合全球創新技術，依託全球優勢資源，研究開發突破性的技術和產品，引領全球糖尿病醫療創新。公司核心產品華堂寧(R)（多格列艾汀片）以葡萄糖傳感器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，華堂寧(R)已獲得中國國家藥品監督管理局（NMPA）的上市批准，用於單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對於腎功能不全患者，無需調整劑量，是一款可用於腎功能損傷的2型糖尿病患者的口服降糖藥物。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com Copyright 2024 亞太商訊 via SeaPRwire.com.

香港, 2024年11月30日 - (亞太商訊 via SeaPRwire.com) - 華領醫藥（「公司」，香港聯交所股份代號：2552.HK）今天在第九屆中國醫藥創新與投資大會（The China BioMed Innovation and Investment Conference，以下簡稱CBIIC）上宣佈，公司已經成功完成與香港中文大學Juliana Chan教授團隊合作開展SENSITIZE研究，該研究為多格列艾汀改善β細胞葡萄糖敏感性的作用機制研究。SENSITIZE研究是由國際內分泌專家、香港中文大學Juliana Chan教授作為研究者發起的，首個在亞洲人群中採用高葡萄糖鉗夾技術評估GKA對不同血糖調節受損人群的β細胞葡萄糖敏感性影響的臨床研究，以探索不同葡萄糖激酶（GK）功能損傷類型在血糖失調方面的臨床特徵和干預手段，為研究亞洲T2D病生理及GK在血糖調控中的核心作用提供了新的科學依據。此次報告的SENSITIZE 2研究結果顯示，採用高葡萄糖鉗夾技術，多格列艾汀單次給藥修復GK酶活性，顯著改善葡萄糖耐量異常（IGT）人群的二相胰島素分泌和β細胞葡萄糖敏感性。而此前在2022年美國ADA年會上報告的SENSITIZE 1研究結果顯示，多格列艾汀可直接修復臨床納入的GK突變型活性，可以顯著改善葡萄糖激酶單基因遺傳突變糖尿病 (GCK-MODY或MODY-2)患者的胰島素第二時相分泌和β細胞葡萄糖敏感性，可以顯著改善初發2型糖尿病患者的基礎胰島素分泌。華領醫藥還將繼續研究多格列艾汀多次給藥對中間高血糖（IH）和2型糖尿病患者β細胞葡萄糖敏感性的修復作用，以及對腸促胰島素的作用，從而建立糖尿病前期和2型糖尿病患者的個性化干預和治療管理方案。關於華領華領醫藥（「本公司」）是一家總部位於中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥匯聚全球醫藥行業高素質人才，融合全球創新技術，依託全球優勢資源，研究開發突破性的技術和產品，引領全球糖尿病醫療創新。公司核心產品華堂寧(R)（多格列艾汀片）以葡萄糖傳感器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，華堂寧(R)已獲得中國國家藥品監督管理局（NMPA）的上市批准，用於單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對於腎功能不全患者，無需調整劑量，是一款可用於腎功能損傷的2型糖尿病患者的口服降糖藥物。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com Copyright 2024 亞太商訊 via SeaPRwire.com.

- 天然氣總銷量達171.3億立方米；- 累計接駁居民、工業和商業用戶分別達到4,795.6萬戶、2.6萬戶及38.5萬戶；- 天然氣順價加快落地 銷氣毛差同比上漲0.02元/m³至0.59元/m³；- 增值服務經營性利潤同比增長15.4%至10.0億港元；- 財務狀況穩健，財務資源豐富，自由現金流達22.2億港元，備用銀行授信及獲批准的人民幣債券總額約1,049.1億等值港元；- 中期派息每股15.0港仙。財務摘要 截至9月30日止六個月 20242023變化千港元千港元%收入35,105,20236,049,154(2.6) 天然氣銷售19,641,83621,718,489(9.6) 燃氣接駁2,027,0382,308,096(12.2) 工程設計、建設及施工 1,308,4871,056,41223.9 液化石油氣（「LPG」）銷售9,557,9768,421,66313.5 增值服務 2,012,9951,804,48611.6 其他業務556,870740,008(24.7)毛利5,855,6955,723,5732.3期間溢利2,263,9152,107,2037.4每股盈利（港仙）32.734.0(3.8)每股中期股息（港仙）15.015.0- 20249月30日20243月31日 變化千港元千港元%總資產153,473,528148,697,7243.2權益總額64,165,44260,747,3535.6銀行結餘及現金9,421,5978,280,33513.8香港, 2024年11月30日 - (亞太商訊 via SeaPRwire.com) - 國內具有領先地位的城市燃氣營運商中國燃氣控股有限公司（「中國燃氣」或「集團」；股票編號：384）宣布其截至2024年9月30日止（「報告期」）之上半財年業績。報告期內，為適時應對複雜多變的國際政治和經濟形勢，中國政府於九月開始推出穩定經濟的措施。在一攬子有利政策的推動下，內地宏觀經濟有望持續回升向好，同時亦為提振天然氣消費需求創造有利條件，城市燃氣企業的盈利能力有望迎來修復，進入一個嶄新發展期。此外，天然氣上下游價格聯動機制在全國範圍內逐步落地，更多地區實現居民終端銷售價格調整，銷氣毛差逐漸修復，進一步支撐天然氣行業的健康及可持續發展。集團秉承「促回款、擴毛差、降費用、強組織、提品質、謀發展」的經營理念，積極探索創新業務的增長新路徑，實現以燃氣業務、增值服務、綜合能源三大核心業務板塊的協同發展。期內，集團錄得營業額351.1億港元，天然氣售氣總量達171.3億立方米，自由現金流表現穩健，達22.2億港元。董事會通過派付上半財年股息每股15.0港仙（2023/24年上半財年：15.0港仙），以回饋廣大股東對集團的長期支持。加快天然氣順價落地，順價比例及毛差進一步提高期內，集團抓住政策機遇，積極響應國家出台的天然氣上下遊價格聯動機制及配氣價格成本監審等政策，推動各地加快順價，集團經營區域內新增20個市/縣落實調價。截至2024年9月30日，集團累計完成居民氣量順價比例達62.2%，毛差修復至0.59元/m³，與去年相比取得穩步提升。期內，借助「老舊小區改造」和「瓶改管」等政策紅利，新接駁904,232戶居民用戶、1,316戶工業用戶及24,906戶商業用戶。截至2024年9月30日，集團累計共為47,955,499戶居民用戶、25,792戶工業用戶及384,504戶商業用戶提供天然氣服務，分別較去年同期增長約3.2%、10.7%和11.6%；集團城市燃氣項目覆蓋的可接駁戶數達5,460萬戶。截至2024年9月30日，集團累計共於30個省、市、自治區取得662個擁有專營權的管道燃氣項目，並擁有32個天然氣長輸管道、509座壓縮/液化天然氣加氣站、一個煤層氣開發項目及120個液化石油氣分銷項目。LPG業務保持高質量發展，持續優化縱向一體化協同作為中國規模最大、產業鏈最完整的綜合性LPG運營服務商，集團業務覆蓋全國22個省、市、自治區，目前運營5座液化石油氣專用碼頭及6座大型石化產品倉儲物流基地，碼頭年吞吐能力超過1,000萬噸，總庫容超過80萬立方米。期內，集團實現銷售液化石油氣201.8萬噸，銷售收入總額達到95.6億港元。集團持續優化縱向一體化協同，就上游而言，集團積極推進核心能力建設，提升國際貿易業務能力。期內，集團重構國際貿易團隊和貿易風控體系，設立新加坡國際直採平台，在國際貿易業務方面取得實質性突破。於中游，集團推進倉儲物流市場化運作，實現倉儲物流資源整合，逐步提升倉儲周轉率，同時啟動國內運貿平台建設，利用數字化賦能，擴大國內分銷能力，從而提高國內分銷與倉儲物流效益。在下游端，集團推動創新業務模式與輕資產模式有效結合，通過迭代優化終端投資模式，豐富投資工具，助力終端業務高質量發展。增值服務營收利潤雙增長，未來發展空間巨大基於家庭場景，集團增值服務佈局3大傳統產品板塊（廚房產品、安防產品、其它產品及服務）及4大新產品板塊（電器、宜居、到家、優選）。目前增值服務業務遍及全國26個省、市、自治區，為用戶提供產品及服務，不斷增加用戶覆蓋，拓寬銷售渠道。今年以來，中國消費市場保持穩定增長態勢，政府出台多項政策鼓勵家電以舊換新和家裝消費品換新工程。集團把握政策機遇，於期內通過加快渠道建設、優化運營策略和強化終端賦能，實現增值服務收入同比增長11.6%至20.1億港元；經營性利潤同比增長15.4%至10.0億港元。目前，集團通過不斷深化傳統渠道運營策略，優化產品結構，加快新業務拓展步伐，借助國家消費扶持政策，進一步擴大市場規模，未來發展空間巨大。積極探索綜合能源業務商業模式，推進重點業務發展集團堅持以「綠色城市運營商」為戰略定位，有效推進多業態融合、優化低能源成本綜合方案以拓展市場、落地可長期發展的多贏商業模式。集團充分利用自身燃氣項目的巨大市場和用戶優勢，通過外延式及內生性增長提升綜合能源業務市場份額。期內，集團積極探索綜合能源業務發展模式，錨定發展重點，投資及運營工商業用戶側儲能、分佈式光伏、鍋爐節能、工商用戶節能、建築能效、充電樁、生物質能等業務。同時積極參與售電業務，並帶動綠電綠證、碳排放因子庫、虛擬電廠等業態快速擴充，為客戶提供高效率的綜合能源，滿足客戶對氣、熱、電、冷的不同需求。期內，儲能及綜合能效業務累計實現簽約總裝機容量318.4MWh，累計投建255.8MWh；售電業務交易量28.1億度；綠證綠電業務完成銷售8,196.4MWh。持續提升安全管理能力，積極推進老舊燃氣管道等設施整改工作集團始終將安全管理視為核心任務，全面識別潜在風險，認真落實隱患整改，持續提升安全管理能力，為集團高質量發展營造安全穩定的環境。期內，集團通過開展專項治理工作，進一步規範基層員工操作，提升員工業務水平，並加强對燃氣管道和相關設施關鍵信息的系統性收集，提升對管網資産的管理水平。同時，借助國家政策支持，集團積極推進老舊燃氣管道和用戶設施老化的更新改造與維護工作。此外，集團不斷加强HSE體系審核認證及體系建設工作，建立健全集團雙重預防機制管理模式，加强安全風險管控與隱患排查治理的閉環管理，並通過積極開展評級檢查，有效提升了項目公司的安全管理水平。財務狀况穩健截至2024年9月30日，集團總資產為1,534.7億港元；銀行結餘及現金為94.2億港元；期內集團通過執行嚴格的外幣債務管理措施，及時合理地調整債務結構。集團一直積極與中國（包括香港）及外資銀行建立長遠合作關係，備用銀行授信及獲批准的人民幣債券總額約1,049.1億等值港元。行業發展及展望國際天然氣價格在經歷兩年劇烈波動後，二零二四年以來重現平衡，供需端亦延續寬鬆態勢。9月下旬開始，中國政府推出一系列穩經濟、強信心的刺激政策，有助於經濟復甦和房地產市場穩定，加上此前推出的「三大工程」、「超長期特別國債」、「老舊管網更新」、「老舊小區改造」、「瓶改管」等利好燃氣行業的政策，有利於穩固燃氣行業根基。與此同時，各省市陸續發布和落實天然氣上下游價格聯動政策，有助於提升銷氣毛差，保障燃氣企業的合理收益，促進天然氣行業的健康長遠發展。此外，全球低碳轉型的浪潮不可阻擋，新能源和綜合能源持續發展。集團將緊抓政策機遇，加快促進順價落地，嚴控資本開支，推動數字化轉型，進一步提升銷氣量及增值服務盈利水平，並全力推動綜合能源項目發展，為國家經濟發展提供「綠色」保障。集團主席兼總裁劉明輝先生表示：「隨著今年九月中國政府推出一系列旨在穩定市場的貨幣及財政政策以促進經濟長期健康發展，相信更多具體、有力的穩經濟政策將陸續出台，這些措施將提振資本市場信心，同時亦為中燃的業務發展提供良好的宏觀環境。在宏觀經濟逐漸向好的大環境下，集團將發揮勇於創新變革的優良傳統，不斷優化業務模式，堅持高質量發展和可持續發展的策略，在不斷做強集團燃氣業務的基礎上，繼續深耕『客戶導向』和『價值創造』，依託產業鏈延伸，拓展用戶側儲能、生物質能等新業務，積極探索宜居、到家等增值服務新業態。同時，集團亦將把握機遇，緊跟政策、用好政策，縝密籌劃，真正把國家政策紅利轉化為集團發展新動能，實現經營業績與股東利益的雙重增長。」有關中國燃氣中國燃氣控股有限公司（「中國燃氣」，股票代號：384）是一家領先的燃氣運營服務商，主要於中國從事投資、建設、經營城市燃氣管道基礎設施，向居民及工商業用戶輸送天然氣和液化石油氣，建設和經營車船用天然氣加氣站。同時，在龐大的燃氣用戶網絡基礎上，中國燃氣打造了增值服務及綜合能源並舉的全業態發展結構。目前中國燃氣在全國已擁有662個城鎮的管道燃氣專營權項目、32個天然氣長輸管道項目、509座壓縮/液化天然氣加氣站，以及液化天然氣等能源產品的進出口經營權，並擁有120個液化石油氣分銷項目。如欲獲得更多中國燃氣的資訊，請登入公司網址http://www.chinagasholdings.com.hk Copyright 2024 亞太商訊 via SeaPRwire.com.

SHANGHAI, Nov 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC).The SENSITIZE study was initiated by Professor Juliana Chan, an international endocrinology specialist at The Chinese University of Hong Kong, as the lead researcher. It is the first clinical study in Asian populations to evaluate the impact of GKA on β-cell glucose sensitivity in the populations with varying degrees of impaired glucose tolerance using the technology of hyperglycemic clamp. The study aims to explore the impairment of glucokinase (GK) function and clinical characteristics in different types of glucose dysregulation, providing new scientific evidence on the pathophysiology of Asian Type 2 diabetes and the central role of GK in blood glucose regulation.The SENSITIZE 2 study results announced at CBIIC demonstrate that a single dose of dorzagliatin restores GK enzyme activity, significantly improving the second-phase insulin secretion and β-cell glucose sensitivity in individuals with impaired glucose tolerance (IGT) in hyperglycemic clamp study. In addition, the SENSITIZE 1 study previously reported at the 2022 ADA annual meeting showed that dorzagliatin directly restores the activity of GK mutants, leading to significant improvements in the second-phase insulin secretion and β-cell glucose sensitivity in patients with glucokinase monogenic diabetes (GCK-MODY or MODY-2), and significantly enhance basal insulin secretion in newly diagnosed type 2 diabetes patients.Hua Medicine will continue to investigate β-cell glucose sensitivity improvement and incretin effect in response of repeated dose of dorzagliatin in individuals with intermediate hyperglycemia (IH) and Type 2 diabetes, in order to establish personalized intervention and treatment management plans for prediabetic and Type 2 diabetes patients.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (Dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.

SHANGHAI, Nov 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC).The Phase Ia clinical trial of the second-generation GKA (HM-002-1005) was conducted in the United States in 40 subjects with Type 2 diabetes (T2D). This trial was randomized, double-blind, placebo-controlled, single-dose, focusing on safety, tolerability, and pharmacokinetics. The second-generation GKA is a novel molecular entity with optimized physicochemical properties, holding new patents, and serving as the prodrug of dorzagliatin (HMS5552). This study designed for once-daily oral administration. Its aim is to extend the drug's action duration in the body through sustained-release technology, enhance patient compliance, and prolong the stimulation of GLP-1 secretion in the intestines.The Single Ascending Dose (SAD) study demonstrates that HM-002-1005 tablets can be rapidly converted to HMS5552 in the human body, with minimal exposure level of prodrug in both blood and urine. The t1/2 (biological half-life) after a single dose of HM-002-1005 tablets was prolonged compared to dorzagliatin tablets. The Cmax of HMS5552 in plasma after a 184.5mg single dose is comparable to the plasma concentration of HMS5552 after a 75mg single dose of dorzagliatin tablet; likewise, the daily AUC of HMS5552 in plasma after a single dose of HM-002-1005 tablets is comparable to the exposure level of HMS5552 after a 75mg BID dose of dorzagliatin tablets. The research indicates that HM-002-1005 tablets are near-completely converted to HMS5552 in human, and its pharmacokinetic characteristics support for once-daily oral administration. The development of HM-002-1005 tablets not only contributes to enhancing patient medication adherence and effectively control blood glucose levels within 24 hours; meanwhile, it also offers the opportunity to explore the Maximum Tolerated Dose above 150mg daily to achieve better efficacy. The 75 mg BID dose regiment was developed under the concept of Minimum Therapeutic Effective Dose in Chinese T2D patients who suffered from an impairment of insulin secretion and significant reduction of early phase insulin. The different disease characters of T2D with obesity in western patient population would benefit dorzagliatin from its effects on GLP-1 secretion and improvement of insulin sensitivity.With the confirmation that the exposure level of HM-002-1005 tablets at 184.5mg is comparable to dorzagliatin tablets at 75mg (BID), we will further optimize the dosage form followed by a Multiple Ascending Dose (MAD) clinical development of the 2nd generation GKA in China and the United States.Dr. Li CHEN, founder and CEO of Hua Medicine, stated, “Hua Medicine has always been committed to treating Type 2 diabetes at its root cause by restoring patients’ ability to autonomously regulate blood glucose levels. Over the course of a decade, the Company has selected dosing and clinical research protocols that are safe and effective for the majority of Chinese diabetes patients, leading to the successful development of GKA and the clinical application of dorzagliatin. Building on this foundation, the Company will undergo a strategic upgrade by further exploring the therapeutic potential of GKA, enriching its product pipeline and seeking partners both domestically and internationally, in order to benefit a broader range of patients, expand into global markets, and effectively establish the brand identity of GKA medications while maximizing the commercial potential of our global first-in-class drugs.”About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (Dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.

業績亮點（截至2024年8月31日止年度經審計之相關數據）- 收入同比增長17%至約人民幣2,312百萬元；- 毛利同比增長10%至約人民幣1,124百萬元；- 本公司擁有人應佔期内利潤同比增長16%至約人民幣715百萬元；- 在校學生人數約95,600人，同比增長11%；- 建議派發末期股息每股10.0港仙；- 全年派息比率30%。香港, 2024年11月29日 - (亞太商訊 via SeaPRwire.com) - 中滙集團控股有限公司 （「中滙集團」或「集團」，股份代號：0382.HK）公布截至2024年8月31日止年度（「報告期」）之經審核2024財年全年業績。報告期內，集團積極響應國家政策，大力推動產教融合，深化國際化辦學內涵，緊貼市場和產業需求不斷開設特色新專業，全面擁抱人工智能（「AI」），辦學質量和教育品牌持續提升，業績逐年穩健增長。於報告期內，集團錄得收入約人民幣2,312百萬元，較去年同期增長17%，主要因集團辦學品牌效益不斷提升，驅動旗下境內學校在校學生人數及平均學費增加。公司擁有人應佔期內利潤同比增長16%至約人民幣715百萬元。在校學生規模逐年擴大，達約95,600人，同比增長約11%。集團董事會建議派發截至2024年8月31日止年度之末期股息每股10.0港仙，連同中期股息每股9.6港仙，全年股息為每股19.6港仙，全年派息比率為30%。由左至右：投融資及投資者關係部總監印國庭先生；首席財務官廖旭東先生；執行董事兼首席執行官廖伊曼女士；首席運營官劉文琦女士。全面擁抱人工智能 持續推動產教融合在過去這一年中，集團見證了新一代人工智能技術的顛覆式發展，作為職業教育辦學者，集團始終與時代發展同頻共振，在教學、管理、應用等各個方面，全面擁抱AI。目前，集團旗下各院校積極推廣、普及AI，已在7個學院開展了AI嵌入課程，此後亦會全面推廣，覆蓋各院校所有師生。同時，集團積極回應國家政策，持續深化產教融合，全力推進產業學院建設工作，攜手多間行業名企共建人工智能與大數據、數字貿易、數智會計與商務服務、研學旅行、珠寶、人力資源等產業學院。該等產業學院均是對標教育部現代產業建設要求，圍繞國家重點產業發展戰略建設，以培養新興產業急需的高質量應用型人才。此外，集團亦與多家知名企業建立校企合作，共建校外實踐基地，進一步推動教育鏈與產業鏈深度融合。擴大國際教育交流合作 深化國際化辦學內涵集團響應國家教育對外開放、「引進來」和「走出去」之倡導，持續推動職業教育國際化進程，擴大與全球知名大學的合作夥伴網絡，透過為學生提供優質國際化課程和實踐機會，培育具全球視野的創新型人才，以期不斷提升中國職業教育的國際影響力。報告期內，集團旗下院校與美國、英國、加拿大、日本、澳大利亞等51所海外高校建立深度合作，攜手打造多樣化的國際精品課程。集團亦全面開展國際研學團，於報告期內先後組織65批學生及教師研學團前往法國、新加坡、中國香港、中國澳門等地短期研學，累計覆蓋師生人數逾4,000名。未來，集團将積極持續深化集團旗下海內外學校共融，竭力構建一個多元化的國際教育合作網絡，積極推動中國職業教育出海，打造國際知名的中國職業教育品牌。持續加大辦學投入 鑄就高質量辦學品牌「創百年名校，育華夏英才」乃是集團始終堅守的辦學理念。集團深信，加大辦學投入是實現高質量教育的重要路徑。報告期內，集團進一步拓建廣州華商學院和廣州華商職業學院新校區，涵蓋學生宿舍、圖書館、體育中心、教學樓和實訓室等，為集團未來招生和可持續發展提供堅實保障。同時，集團亦在師資隊伍建設方面亦不斷加大投入。隨著廣州華商學院及廣州華商職業學院廣東省博士工作站的相繼設立，集團的師資隊伍日益壯大。集團開展了一系列教師培訓工作坊，持續增強教師專業素養和實踐教學能力，鼓勵教師們將所學應用於實踐，推動學校教育教學水平的提升；亦通過引進行業導師，與企業共同培養「雙師型」專業教師和「雙能型」產業導師，不斷優化專兼結合師資隊伍結構。集團在教育的各個關鍵領域進行了深入而精准的投入，持續強化辦學內涵，並取得諸多碩果。旗下廣州華商學院的科研競爭力位列中國民辦本科院校第3名、亦為廣東省普通高校人文社會科學重點研究基地；廣州華商職業學院評委全國示範性職業學校；四川城市職業學院位列軟科2024中國民辦高職院校全國第2名、四川省第1名等等，這些榮譽，是集團高質量辦學成果最有力的證明。展望未來，集團將繼續堅持創新型人才培養模式，通過在產教融合、國際化、AI等多個方面重點發力，緊貼產業和社會發展需求，加大辦學投入，持續打造高質量辦學品牌，竭力為國家和全球各行各業培養高技能、複合型的企業領袖，持續為推動中國職業教育事業可持續發展作出積極貢獻。關於中滙集團控股有限公司中滙集團控股有限公司（「中滙集團」或「集團」，股份代號：0382.HK）為粵港澳大灣區最大的民辦商科高等及職業教育集團，及教育行業中拓展國際市場的早期先行者，於2019年7月16日在香港主板上市。截至2024年8月31日，集團的全日制在校學生人數約9.6萬人，旗下擁有9間民辦教育機構，分別是：位於中國廣東省的廣州華商學院（應用型本科）、廣州華商職業學院（高等學歷職業教育）、廣東華商技工學校（中等學歷職業教育）；位於中國四川省的四川城市職業學院（高等學歷職業教育）、四川城市技師學院（中等學歷職業教育）；位於中國香港的大灣區商學院 GBA Business School（GBABS）；位於澳大利亞的澳洲國際商學院Global Business College of Australia（GBCA）、澳大利亞中滙學院Edvantage Institute Australia（EIA）；以及位於新加坡市區的新加坡中滙學院Edvantage Institute (Singapore)（EIS）。集團在專注辦學的同時，也積極承擔企業社會責任，在慈善民生、鄉鎮扶貧、教育振興等社會公益事業廣泛開展社會貢獻活動，以實際行動主動履責，積極回饋社會。自上市以來，集團在ESG領域貢獻突出，並於2024年榮獲智通財經「最佳ESG創新」獎、格隆匯「ESG創新實踐卓越企業」獎。 Copyright 2024 亞太商訊 via SeaPRwire.com.

香港, 2024年11月29日 - (亞太商訊 via SeaPRwire.com) - 近日，由粵港澳大灣區上市公司聯合會主辦的"2024首屆粵港澳大灣區上市公司高峰論壇"在香港成功舉辦。現場，五菱汽車（00305.HK）憑藉優秀的ESG表現，榮獲大灣區上市公司ESG100綠色發展"年度企業管治獎"！ 據瞭解，本次高峰論壇活動主題為"立足香港 聯通灣區 走向世界"，特邀政府領導、行業專家和港股、A股企業代表逾300位嘉賓齊聚香港，共商發展大計。當天論壇正式啟動了"香港-粵港澳大灣區上市公司總部最佳選擇"倡議、粵港澳大灣區上市公司聯合會ESG、產業併購、IPO"三駕馬車"以及"100+粵港澳大灣區上市公司借港出海聯盟"。此外，125家A股、港股等上市公司參與「大灣區上市公司ESG100綠色發展五項大獎」頒獎典禮。五菱汽車集團控股有限公司財務總監及公司秘書黎士康出席論壇，代表五菱汽車領取大灣區上市公司ESG100綠色發展"年度企業管治獎"。一直以來，五菱汽車深知在促進企業穩健發展的同時，履行社會責任同樣重要。公司一直不斷深化改革和轉型升級，將環保及社會責任融入企業發展戰略，打造成為可持續發展的優秀企業。在環境保護方面，五菱汽車不斷完善環境保護的管理體系，在生產過程中實行節能減排的措施，努力達至"綠色工廠"的標準。公司並由"綠色製造"轉向"製造綠色"，積極引入先進技術以推出新能源汽車，開發綠色交通的建設。在公司與員工治理方面，五菱汽車一直以"安全第一、以人為本"為宗旨，以員工的權益為先，重視員工培訓、職業發展及工作安全，建立良好的企業氛圍。在關懷社會方面，公司主動承擔企業責任，是國家及廣西區重大公益活動的活躍成員，並持續組織及參與慈善公益活動，為不同的社區奉獻愛心。值得注意的是，在近期S&P全球ESG評級公佈的最新報告中，五菱汽車提供了83%和55%的必要披露和額外披露，數據可用性在ATX汽車零部件行業中很高。在此基礎上，通過對環境、治理和經濟、社會多個維度的專業分析，五菱汽車ESG評分獲得43，在行業內表現優異。各維度來看，五菱汽車在環境保護、社會責任及企業治理評分均遠高於行業平均水平的38、36、37。標普全球ESG評分（S&P全球ESG）在SAM企業可持續性評估(CSA)發佈的深入信息的支持下，以61個行業特定方案和對公司爭議的監測情況為指導，提供對行業特定風險和機遇的評估。而CSA集全面的數據源、合理的方法論和對重大問題的密切關注於一體，是全球可持續發展專業人士和投資者公認的"最優質"且"最有用"的ESG評估之一。五菱汽車在權威ESG評分中獲得良好成績以及獲得大灣區上市公司ESG100綠色發展"年度企業管治獎"，是對五菱汽車企業治理的高度認可和公司業內良好口碑的充分證實。五菱汽車表示：站在新時代的起跑線上，公司抓緊當前機遇，着眼長遠發展，深化改革創新，培育發展新動能，以實現可持續、高質量發展，承載責任與希望，在汽車行業留下更加濃墨重彩的華章。 Copyright 2024 亞太商訊 via SeaPRwire.com.

香港, 2024年11月29日 - (亞太商訊 via SeaPRwire.com) - 香港董事學會昨晚在香港會議及展覽中心舉行的香港董事學會週年晚宴上公布2024年度董事嘉獎系列得獎者。獎項系列包括歷來備受推祟的「傑出董事奬」及今年最新啟動的「氣候管治獎」。香港董事學會主席陶榮博士致辭並掀開晚宴序幕，亦邀請了大紫荊勳賢、香港特別行政區非官守議員鄭慕智博士、中聯辦經濟部徐衛剛部長、財經事務及庫務局常任秘書長(財經事務)甄美薇女士, JP以及證券及期貨事務監察委員會主席、會計及財務匯報局主席黃天祐博士，SBS ，JP擔任主禮嘉賓。今屆報名參賽者十分踴躍，引發評審團熱烈討論。獲獎者包括董事和董事會在內共19 名，充份演繹今年獎項主題「靈活領導 創意年代」真諦。獲獎者不僅展現組織靈活性，更在嚴峻的營商環境和地緣政治緊張局勢中發揮了領導者的遠見、勇氣和智慧。此外，董事們更承擔起帶領團隊辨析氣候變化所帶來的危與機，以及對全球永續發展和人類福祉所帶來的深遠影響。以下為2024年度董事嘉獎系列得獎者:- 傑出董事簡稱「DYA」- 氣候管治獎簡稱「CGA」排名以英文名稱字母為序上市公司 執行董事DYA陳偉明先生登輝控股有限公司CGA陳婉珊女士利記控股有限公司DYA傅帆先生中國太平洋保險（集團）股份有限公司CGA李偉樑先生恒安國際集團有限公司黃維義先生香港中華煤氣有限公司DYA & CGA顏建國先生中國海外發展有限公司非執行董事DYA鍾瑞明博士中國中鐵股份有限公司曾憲章博士TCL電子控股有限公司王一江教授TCL電子控股有限公司 董事會DYA & CGA華潤啤酒(控股)有限公司CGA香港中華煤氣有限公司DYA & CGA中國平安保險（集團）股份有限公司CGA俄鋁非上市公司執行董事DYA陳雲美女士屈臣氏實業CGA鄭文聰教授正昌科技(集團)有限公司鄭世有博士工程師奧雅納DYA柯家洋先生穩健醫療(香港)有限公司法定／非分配利潤組織董事會DYA香港旅遊發展局另獲:董事會多元化卓越嘉許國際內部審計師協會（IIA）香港分會理事會另獲:董事會多元化卓越嘉許前排的主禮嘉賓、官員以及香港董事學會的理事會成員一同和後排實至名歸的得獎者合照。「香港董事學會董事嘉獎系列」「香港董事學會董事嘉獎系列」是香港董事學會（簡稱「學會」）舉辦的一個項目，包含兩個獎項系列。第一個系列是「傑出董事奬」，自2001年舉辦，為首次在亞洲的創舉。由於董事最終負責企業管治，以及帶領公司實現繁榮和誠信，該獎項宗旨為彰顯傑出董事會和董事，並推廣優秀企業管治和董事專業行為。該獎項現已成為學會每年推動具影響力的一個社區項目，並得到100多個合作夥伴的支持。迄今，255位獲獎者已因在企業管治和董事常規中展現卓越的標準而受到表彰。2024年啟動的「氣候管治獎」構成學會獎項的第二個系列。該獎項著眼於彰顯及啓發董事及董事會在氣候管治的優秀成就，並提倡董事們採取有關氣候的行動。首屆獲獎者共10位。現在是董事必須在董事會議程和管治職務中處理因氣候變化帶來風險和機遇的關鍵時刻。候選人可由公眾提名，其資料透過嚴格的程序進行處理，經過與甄選顧問作高度盡職調查的會面，最後由擁有高標準和公正判斷的獨立評審團選出。獎項按公司類別，即上市公司、非上市公司和法定/非分配利潤組織，亦按職務，即執行董事、非執行董事和董事會，進行頒發。香港董事學會（簡稱"HKIoD"，又以下簡稱「學會」）香港董事學會為香港代表董事共同努力的首要組織，其宗旨是促進企業永續發展職能，為所有公司、其擁有者、持份者、人類以至地球創造持久價值；為達成使命，學會致力於企業管治（「企業管治」又稱「公司治理」）及董事專業行為上的倡導及釐定相關標準。學會於1997年由創會主席鄭慕智博士帶領下創始，多年來非常榮幸獲得香港特別行政區行政長官擔任學會贊助人。學會會員來自不同行業及公司類別，並包括執行董事、非執行董事、獨立非執行董事。學會以多元文化及國際視野進行會務，舉辦活動包括董事培訓課程、研討會與論壇、董事立場喉舌、指引設定、公眾教育、董事嘉獎系列、上市公司管治水平釐定等。作為「董事學會環球網絡」（Global Network of Director Institutes 簡稱"GNDI")的成員組織，學會投入全球性聯手推動優秀企業管治及董事專業行為。學會亦獲委派代辦「氣候管治行動」(Climate Governance Initiative)之香港分部，該行動是與「世界經濟論壇」（World Economic Forum）合作的環球網絡，積極促進董事們處理氣候變化帶來的風險與機遇。詳情請瀏覽：http://www.hkiod.com | http://www.gndi.org | https://climate-governance.org/新聞垂詢：董事嘉獎系列獎查詢：縱橫公共關係顧問集團有限公司香港董事學會陳練 +852 2114 4396 / brenda.chan@sprg.com.hk蘇佩君 +852 2889 9986/ odessa.so@hkiod.com Copyright 2024 亞太商訊 via SeaPRwire.com.

SAN FRANCISCO, CA & MUMBAI, Nov 28, 2024 - (ACN Newswire via SeaPRwire.com) - Niyo, India’s leading fintech startup, teamed up with CleverTap, the all-in-one engagement platform, to improve customer experiences through personalized engagement and real-time interactions. Since its founding in 2015, Niyo has been revolutionizing financial services in India, particularly with its international travel cards and app-based financial services, catering to the evolving needs of its users.In its almost decade-long journey, Niyo recognized the challenges that modern Indian travellers face at every touchpoint while venturing abroad. It sought a feature-rich user engagement platform that would effectively deliver the right solutions to its customers and found the ideal partner in CleverTap. By leveraging CleverTap’s advanced automation tools, Niyo enhanced its onboarding processes, while ensuring compliance with regulations, and streamlining customer experiences. This collaboration empowered Niyo to reduce drop-offs during the customer journey, automate personalized messages, and re-engage dormant users.By deploying CleverTap’s integrated platform, Niyo achieved:・2x increase in click through rates, leveraging Clever.AI for emotionally intelligent content.・40% optimized conversion rate through pinpoint targeting, ensuring personalized and relevant communication at every step.・12% re-engagement of dormant users through targeted campaigns, highlighting Niyo’s success in winning back inactive customers.Sushanth Ravikumar, SVP - Head of Marketing, Niyo, said - “At Niyo, delivering a seamless and personalized experience for our customers is a top priority. CleverTap has been instrumental in elevating this experience. Its robust automation and communication tools have streamlined our onboarding process while maintaining compliance in the highly regulated sector. What started as a tool to streamline everyday operations has become a key force in helping us preserve customer trust, even during challenging times. Its ability to adapt to real-time shifts in customer engagement offers us a definitive edge in an ever-changing dynamic, solidifying our long-term confidence in the platform.”Sidharth Pisharoti, Chief Revenue Officer, CleverTap, said - “We are excited to collaborate with Niyo as they continue to innovate in the travel fintech space. Through our partnership, we’ve been able to enhance Niyo’s customer engagement by focusing on delivering personalized and timely experiences. This has not only streamlined their processes but also improved customer satisfaction, particularly in key areas like onboarding and transaction management. We look forward to supporting Niyo as they scale and evolve their offerings in this dynamic market.”About Niyo Niyo is India’s leading banking fintech that has revolutionized "travel banking" for Indians. The company was co-founded by banking veteran Vinay Bagri (currently, CEO) and technology veteran Virender Bisht (currently, CTO) in 2015. Niyo offers zero forex debit and credit cards, which provides the best banking experience and value for international travellers. This unique solution was invented by Niyo in 2015 and has helped over 2 million Indians by saving more up to 5% on their international transactions with Zero Forex offering. In this last Series-C round in 2022, Niyo raised $130 million, which was led by global VC and PE firms, Accel, Lightrock, and Multiples. Its other investors include Prime Venture Partners, Horizons Ventures, Tencent, JS Capital, Social Capital, and Beams Fintech Fund. Niyo operates out of a corporate office in Bengaluru and has a sales presence in more than 20 states and union territories.Visit: GoNiyo.comAbout CleverTapCleverTap is the leading all-in-one customer engagement platform that helps brands unlock limitless customer lifetime value. CleverTap is trusted by over 2000 brands like Decathlon, Domino’s, Levis, Jio, Emirates NBD, Puma, Croma (A Tata Enterprise), Swiggy, SonyLIV, Axis Bank, AirAsia, TD Bank, Ooredoo, and Tesco, to help build personalized experiences for all their customers. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering speed and cost efficiency at scale.Backed by top-tier investors such as Accel, Peak XV Partners, Tiger Global, CDPQ and 360 One, the company is headquartered in San Francisco, with presence across Seattle, London, São Paulo, Bogota, Mexico, Amsterdam, Sofia, Dubai, Mumbai, Bangalore, Singapore, Vietnam, and Jakarta.For more information, visit CleverTap.com or follow us on:LinkedIn: https://www.linkedin.com/company/clevertap/ X: https://twitter.com/CleverTap Forward-Looking StatementsSome of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release.Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction.For more information:SONY SHETTYDirector, Communications and CSR, CleverTap+91 9820900036sony@clevertap.com ASHMIT CHAUDHARYAssociate Consultant, Archetype+91 8850752121ashmit.chaudhary@archetype.co Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Nov 28, 2024 - (ACN Newswire via SeaPRwire.com) - China’s largest retail digitalization solution provider – Dmall Inc. (“Dmall” or the “Company”, Stock Code: 02586.HK), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited (“Hong Kong Stock Exchange”).Dmall plans to offer 25,774,000 Shares (subject to the over-allotment option), of which 23,196,600 Shares will be International Offer Shares (subject to reallocation and the over-allotment option), representing approximately 90% of the initial offer shares; the remaining 2,577,400 Shares will be Hong Kong Offer Shares (subject to reallocation), representing approximately 10% of the initial offer shares. The Offer Price is HK$30.21 per Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Hong Kong Stock Exchange trading fee of 0.00565% and Accounting and Financial Reporting Council transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund).Dmall will open for Hong Kong Public Offering in Hong Kong at 9 a.m., November 28, 2024 (Thursday), and close at 11:30 a.m., December 3, 2024 (Tuesday). Dealings in shares of Dmall on the Main Board of the Hong Kong Stock Exchange is expected to commence on December 6, 2024 (Friday). The shares will be traded in board lot of 100 shares each. The Company’s stock code will be 02586.HK.UBS Securities Hong Kong Limited, CMB International Capital Limited and China Merchants Securities (HK) Co., Limited are the Joint Sponsors. UBS AG Hong Kong Branch, CMB International Capital Limited, China Merchants Securities (HK) Co., Limited, CLSA Limited and China International Capital Corporation Hong Kong Securities Limited are the Joint Global Coordinators, Overall Coordinators, Joint Bookrunners and Joint Lead Managers.After deducting the underwriting commissions and other estimated offering expenses payable by the Company, with an Offer Price of HK$30.21 per Offer Share, the Company estimates that it will receive net proceeds of approximately HK$623.7 million from the Global Offering after deducting the underwriting commissions and fees, and other estimated expenses in connection with the Global Offering and assuming that the Over-allotment Option is not exercised. In line with Dmall’s strategies, the proceeds from the Global Offering are intended to be used for the following purposes and in the following amounts – approximately 42.1%, or HK$262.6 million, to develop new applications and new service modules; approximately 30.0%, or HK$187.1 million, for talent acquisition associated with the expansion of Dmall’s operations; approximately 10.0%, or HK$62.4 million, to selectively pursue strategic cooperation, investments and acquisitions that are complementary to its organic growth strategies, particularly those that can complement Dmall’s product offerings, strengthen its technology capabilities, and solidify its market position; approximately 7.9%, or HK$49.3 million, to expand its sales network and further strengthen its brand reputation; and approximately 10.0%, or HK$62.4 million, for working capital and general corporate purposes.Dmall was founded in 2015, which provides retail digitalization solutions to retailers in the local retail industry. According to Frost & Sullivan, Dmall is the largest retail cloud solution provider in China by GMV, with a market share of 13.3% in 2023. The expansion has allowed the Company to become the largest retail cloud solution provider in Asia by GMV in 2023, occupied a market share of 10.9%, according to Frost & Sullivan.As a leading retail digitalization solution provider in Asia, the broadest operational modules coverage enables Dmall to cover diverse customer base in the retail industry and thus obtain deep retail know-how, meet the needs of all major aspects of the retailer's operations. Dmall served 444 customers in the six months ended June 30, 2024, such as Pangdonglai, Luosen (China), Dennis and Maidelong Entities, as well as well-known brands such as Wellcome, Mannings, Guardian, Giant and 7-Eleven (Hong Kong), which operate under the DFI Retail Group, demonstrating a widely validated operating model. The dollar-based net retention ratio was 184% in 2021, 158% in 2022, 117% in 2023 and 123% in the twelve months ended June 30, 2024, remaining robust at above 100%, which underscores Dmall’s ability to further increase customer spending.Dmall has always attached importance to the value created for customers, “customer success” is the starting point of everything the Company does. Dmall has provided services to leading companies in different retail formats, and has successfully expanded its businesses markets outside of the Chinese mainland, comprising Hong Kong SAR, Cambodia, Singapore, Malaysia, Poland, Macau SAR, Indonesia, the Philippines and Brunei. In terms of income, the overseas income of the Company in 2023 has exceeded RMB100 million.Dmall achieved strong revenue growth as its revenue grew by 56.6% from RMB848.2 million in 2021 to RMB1,328.3 million in 2022, and further increased by 19.4% to RMB1,585.4 million in 2023. Dmall’s revenue increased by 22.9% from RMB764.0 million in the six months ended June 30, 2023 to RMB939.2 million in the six months ended June 30, 2024. Dmall has also improved its gross margin during the Track Record Period. Dmall’s gross margins were 20.4%, 38.0%, 35.0%, 36.3% and 38.3% in the years ended December 31, 2021, 2022, 2023 and the six months ended June 30, 2023 and 2024, respectively.Mr. Zhang Feng, co-founder, executive Director and president of Dmall said, “We empower retailers to thrive in the digital era and are committed to becoming the world's leading omnichannel retail digital solutions provider. We will uphold the values of "continuous innovation", always strive, constantly strengthen and uphold our own technical barriers and optimize products and services, maintain core competitiveness, continue to provide customers with high-value services, and help customers' business. We look forward to taking the listing as an opportunity to fully leverage our competitive advantages and utilize Hong Kong's unique financing platform to further enhance our strengths and continue to create greater value for our shareholders and investors.”Issued by Porda Havas International Finance Communications Group for and on behalf of Dmall Inc. For further information, please contact:Porda Havas International Finance Communications GroupMS.Fung Kelly(852) 3150 6763kelly.fung@h-advisors.globalMS.Wang Evie(86) 135 2006 8960evie.wang@h-advisors.global Copyright 2024 ACN Newswire via SeaPRwire.com.

Highlights (relevant audited data for the year ended 31 August 2024)- Revenue increased by 17% YoY to approximately RMB2,312 million;- Gross profit rose by 10% YoY to approximately RMB1,124 million;- Profit for the period attributable to owners of the Company rose by 16% YoY to approximately RMB715 million;- Number of student enrolments increased by 11% YoY to approximately 95,600;- Payment of a final dividend of HK10.0 cents per share;- Dividend payout ratio of 30% for the year.HONG KONG, Nov 29, 2024 - (ACN Newswire via SeaPRwire.com) - Edvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK) has announced its audited FY2024 Annual Results for the year ended 31 August 2024 (the “Reporting Period”). During the Reporting Period, the Group actively responded to national policies, vigorously promoted industry-education integration, deepened the connotations of international education, continued to introduce unique new featured majors that match market and industry demands and fully embraced artificial intelligence (“AI”), succeeding in raising education quality and brand presence, thereby achieving steady growth in performance year after year.During the Reporting Period, the Group’s revenue totaled approximately RMB2,312 million, representing an increase of 17% as compared to the corresponding period of the preceding year. The increase was mainly attributable to the continuous enhancement of the Group’s education brand effectiveness, which drove a rise in the number of student enrolments and higher average tuition fees recorded by the Group’s domestic schools. Profit for the period attributable to owners of the Company rose by 16% YoY to approximately RMB715 million. The number of students enrolled in the Group’s schools continued to expand yearly, reaching approximately 95,600, with a year-on-year growth of approximately 11%. The Board of Directors of the Group has recommended the payment of a final dividend of HK10.0 cents per share for the year ended 31 August 2024, which, along with an interim dividend of HK9.6 cents per share, equates to a total annual dividend of HK19.6 cents per share and a dividend payout ratio of 30% for the year.From left to right: Mr. Yan Kwok Ting Sunny, Director of Investment, Corporate Finance & Investor Relations Department;Mr. Liu Yuk Tung, ChiefFinancial Officer; Ms. Liu Yi Man, Executive Director and Chief Executive Officer;Ms. Liu Wenqi, Chief Operating Officer;Fully embracing AI and continuously promoting the industry-education integrationOver the past year, the Group witnessed the groundbreaking development of the new generation of artificial intelligence technology. As a vocational education provider, the Group has developed in step with times, fully embracing AI in teaching, management and application. At present, all of its schools are actively promoting AI, fostering its popularity, with AI-embedded courses launched in seven colleges. Subsequent efforts will be made to promote those programmes to cover all faculties and students of all schools under the Group. Meanwhile, the Group actively responded to national policies, continuously deepened industry-education integration, and fully promoted the construction of industrial colleges, cooperating with multiple enterprises renowned in their respective industries to establish artificial intelligence and big data, digital trade, digitalised accounting and business services, research and tourism, jewelry, human resources and other industrial colleges. Those industrial colleges are all set up according to the Ministry of Education requirements for building modern industrial colleges that align with the country’s key industry development strategies, in order to nurture high-quality application-minded talent that emerging industries urgently need. In addition, the Group also entered into school-enterprise cooperation with numerous enterprises to build off-campus practice bases, further promoting the in-depth integration of education chains and industrial chains.Expanding exchange and cooperation of international education and deepening the connotations of international educationThe Group responded to the national advocacy for the opening up of education, “introduction of foreign schools”, and “international expansion of domestic schools”, continuously promoted the internationalisation of vocational education and expanded the partnership network with global renowned universities. By providing high-quality international programs and practice opportunities to students, the Group aims to cultivate innovative talents with global vision, to further raise the international influence of China’s vocational education. During the Reporting Period, the schools under the Group established in-depth cooperation with 51 foreign high schools in the United States of America, the United Kingdom, Canada, Japan and Australia, joining hands to create diverse high-quality international programmes. Furthermore, the Group comprehensively launched international study tours, organising 65 student and teacher study tours to France, Singapore, Hong Kong, China, Macau, China and other regions for short-term studies, with over 4,000 teachers and students participating during the Reporting Period. Looking forward, the Group will press on with deepening integration of its schools - domestic and international, strive to build a diversified international education cooperation network, actively promote Chinese vocational education to go global and build an internationally renowned Chinese vocational education brand.Consistently increasing investment in education to build a high-quality education brandThe Group has always adhered to the motto of "Establishing school of the century, Nurturing talents of the nation". Firmly believing that increasing investment in education is an important path towards high-quality education, the Group further expanded the new campus of Guangzhou Huashang College and Guangzhou Huashang Vocational College during the Reporting Period, which includes student dormitories, library, sports centre, teaching buildings and laboratories, providing solid support for future student enrollment and sustainable development of the Group. At the same time, it has kept increasing investment in building a high-quality teaching staff, which has expanded after the Guangzhou Huashang College and Guangzhou Huashang Vocational College established their Guangdong Province Doctoral Workstation respectively. The Group has launched a series of training workshops for teachers to continuously enhance their professionalism and practical teaching abilities, encouraging them to practice what they have learned and help improve school education and teaching quality. By introducing mentors from industries, it works together with enterprises in nurturing professional “dual-qualified” teachers and “dual-skilled” industry mentors, continuing to optimize the combined structure of full-time and part-time faculty teams. The in-depth and precise investment made by the Group in various areas crucial to strengthening school management has brought bountiful results. Guangzhou Huashang College placed third in scientific research competitiveness among private undergraduate colleges in China and has been designated as a key research base for humanities and social sciences among regular higher education institutions in Guangdong Province. Guangzhou Huashang Vocational College has been named a national exemplary vocational college, while the Urban Vocational College of Sichuan ranked second in China and first in Sichuan among Shanghai Ranking's 2024 Best Chinese Private Higher Vocational Colleges. These honors are a strong testament to the Group’s high-quality educational achievements.Looking ahead, the Group will continue to nurture innovative talent, focusing on such areas as industry and education integration, internationalization, and AI to keep up with industry and social development needs, increase investment in education, and keep building a high-quality education brand. It is committed to nurturing highly-skilled interdisciplinary corporate leaders for the country and industries around the world, while continuously making positive contributions to the sustainable development of vocational education.About Edvantage Group Holdings LimitedEdvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK) is the largest private business higher education and vocational education group in the Greater Bay Area, and an early mover in education sector in pursuing international expansion, listed in Hong Kong Main Board on 16 July 2019. The total number of full-time student enrolments of the Group was approximately 96,000 as of 31 August 2024. Operated 9 private education institutions, namely, Guangzhou Huashang College (Applied Undergraduate), Guangzhou Huashang Vocational College (Higher Vocational Education) and Guangdong Huashang Technical School (Secondary Vocational Education) located in Guangdong Province, the PRC; Urban Vocational College of Sichuan (Higher Vocational Education) and Urban Technician College of Sichuan (Secondary Vocational Education) in Sichuan Province, the PRC; GBA Business School (GBABS) in Hong Kong, the PRC; Global Business College of Australia (GBCA) and Edvantage Institute Australia (EIA) in Australia; as well as Edvantage Institute (Singapore) (EIS) in the downtown of Singapore.While focusing on school operations, the Group also actively fulfil corporate social responsibility, extensively contributing to social welfare programmes including charity, poverty alleviation, education and revitalisation, in order to take the initiative in repaying society through action. Since its listing, the Group has made outstanding contributions in the field of ESG and has won the “Best ESG Innovation Award” from Zhitong Finance and the “Outstanding Enterprise for ESG Innovative Practice” from Gelonghui in 2024. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Nov 29, 2024 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Institute of Directors ("HKIoD") announced the winners of its Award Series for Director Excellence (the "Awards") – comprising the long-established Directors of the Year Awards ("DYA") and the inaugural Climate Governance Awards ("CGA"), at its Annual Dinner yesterday at the Hong Kong Convention and Exhibition Centre. The event began with an opening speech by Dr Christopher To, Chairman of the HKIoD. Dr The Hon Moses Cheng Mo Chi, Non-official Member of the Executive Council of HKSARG, Mr Xu Wei Gang, Director General, Department of Economic Affairs, Liaison Office of the Central People's Government in HKSAR, Ms Salina Yan, JP, Permanent Secretary for Financial Services and the Treasury (Financial Services), and Dr Kelvin Wong, Chairman, Securities and Futures Commission ("SFC") and Chairman, Accounting and Financial Reporting Council ("AFRC") were invited as guests of honour. The response to the Awards submissions was overwhelmingly positive. After a lively discussion among the judges, this year's 19 winners, including directors and boards, were selected - all embodying the theme "Leading with Agility in an Era of Innovation". The awardees have demonstrated not only agility, but also the vision, courage and wisdom to lead against the backdrop of a demanding economic environment and prevailing geopolitical tensions. Moreover, they highlight the importance of having directors who can guide their companies in identifying the risks and opportunities associated with climate change, which are vital for ensuring the sustainability of the world and humanity.The Awardees of HKIoD Award Series* for Director Excellence 2024 are listed below:*Two series of Awards:- "DYA", acronym for "Directors Of The Year Awards"- "CGA", acronym for "Climate Governance Awards"In alphabetical order of names within categoryListed Companies CategoriesExecutive DirectorsDYAMr Chan Wai MingTown Ray Holdings LimitedCGAMs Clara Chan Yuen-shanLee Kee Holdings LimitedDYAMr Fu FanChina Pacific Insurance (Group) Co., LtdCGA Mr Li Wai LeungHengan Internationals Group Company LimitedMr Peter Wong Wai-YeeThe Hong Kong and China Gas Company LimitedDYA & CGAMr Yan Jianguo JPChina Overseas Land & Investment LimitedNon-Executive DirectorsDYA Dr Chung Shui Ming TimpsonChina Railway Group LimitedDr Tseng Shieng-chang CarterTCL Electronics Holdings LimitedProf Wang YijiangTCL Electronics Holdings LimitedBoardsDYA & CGAChina Resources Beer (Holdings) Company LimitedCGAHong Kong and China Gas Company LimitedDYA & CGAPing An Insurance (Group)Company of China, LtdCGAUnited Company RUSAL, international public joint-stock companyNon-listed Companies CategoriesExecutive DirectorsDYAMs Michelle ChanAS Watson IndustriesCGA Ir Prof Daniel M.ChengDunwell Technology (Holdings) Limited) (Dunwell Group)Ir Dr Cheng Sai Yau, VincentArup Fellow and Director of Climate and Sustainability in East AsiaDYAMr Orr Ka-yeung KevinWinner Medical (Hong Kong) LtdStatutory/ Non-profit-distributing Organisations CategoriesBoardsDYAHong Kong Tourism Board*In addition: recognition of Excellence in Board DiversityThe Institute of Internal Auditors Hong Kong*In addition: recognition of Excellence in Board DiversityThe guests of honour, special guests and officials to join the group photos together with the awardees (2nd row).About "HKIoD Award Series for Director Excellence"The HKIoD Award Series for Director Excellence is a project organised by The Hong Kong Institute of Directors ("HKIoD") and consists of two series of Awards.The first series, Directors Of The Year Awards, was inaugurated in 2001 as the first ever such Awards organised in Asia. As directors are ultimately responsible for corporate governance and leading the company in prosperity and integrity, the objectives of the Awards are to recognise outstanding boards and directors and to promote good practices in corporate governance and director professionalism. The Awards have become an annual project of impact in the community organised by HKIoD together with over 100 Project Partners. To date, 255 Awardees have been recognised for their achievements in demonstrating exemplary high standards in corporate governance and director practice.Inaugurated in 2024, Climate Governance Awards constitute the second series of HKIoD Awards with the objectives to recognise and inspire exemplary achievements in climate governance and to advocate climate action by directors. There are 10 awardees who have been acknowledged in the inaugural edition of the awards. It is critical time now for directors to address the risks and opportunities of climate change in board agendas and their governance role.Candidates are open to public nomination, with data processed in well-defined and stringent procedures, followed by interviews with independent consultants in utmost due diligence and finally selected by independent judges with high standards and fair judgment. Awards are presented by company categories, viz Listed Companies, Non-listed Companies and Statutory/Non-profit-distributing Organisations, and by capacities, viz Executive Directors, Non-Executive Directors and Boards.About The Hong Kong Institute of Directors ("HKIoD")The Hong Kong Institute of Directors ("HKIoD") is Hong Kong's premier body representing directors working together to advance corporate sustainability in creating long-term value for companies, their owners, stakeholders, humankind and Planet Earth through advocacy and standards-setting in corporate governance and director professionalism. Led by Founder Chairman Dr The Hon Moses Cheng, HKIoD was founded in 1997. Throughout the years, HKIoD is honoured to have the Chief Executive of HKSAR as the Institute's Patron. Membership of HKIoD comprises of directors from diverse industries and corporate types and includes Executive Directors, Non-Executive Directors and Independent Non-Executive Directors. With multi-culturalism and international perspectives, HKIoD organises activities that cover director training, seminars and forums, collective director voice, guideline establishment, public education, Award Series for Director Excellence, assessment of Corporate Governance Scorecard for listed companies etc.As a member body of the Global Network of Director Institutes ("GNDI"), HKIoD is committed to global collaboration in promoting good corporate governance and director professionalism. HKIoD is the appointed Host of the Hong Kong Chapter of Climate Governance Initiative, a global network that collaborates with the World Economic Forum in actively promoting directors' address of the risks and opportunities of climate change.For details please visit:http://www.hkiod.com|http://www.gndi.org|https://climate-governance.org/Media Enquiries:Award Series for Director Excellence:Strategic Public Relations Group LimitedThe Hong Kong Institute of DirectorsBrenda Chan+852 2114 4396/ brenda.chan@sprg.com.hkOdessa So +852 2889 4988/ odessa.so@hkiod.com Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年11月29日 - (亞太商訊 via SeaPRwire.com) - 本港步入高齡化社會，為滿足對優質養老之龐大需求，中銀集團人壽保險有限公司（「中銀人壽」）正式啓動全球旅居養老金融佈局，聯動中國銀行（香港）（「中銀香港」）發揮「銀行+保險」優勢，率先推出「旅․心活」旅居體驗計劃（「旅․心活」）[1]，讓港人以嶄新的旅居方式，於「低物價指數、高生活品質」的宜居城市感受不同風土人情，深度體驗以「六養合一」為理念的退休養老生活，盡情探索第二人生。「旅․心活」首階段覆蓋內地18大宜居城市，其中包括大灣區9個城市（除港澳外）；整體佈局先聚焦大灣區及華南華東地區，再輻射全國，後至東南亞及全球。中銀人壽同時提供一系列針對財富增值傳承、退休年金及每月入息之保險產品，協助客戶創造穩定現金流，建立養老生活財務支付基礎，配合全新會員制旅居體驗計劃，加上中銀香港跨境支付配套及專屬消費優惠，讓客戶實踐退休後動態慢活新方式。中銀人壽率先推出市場首創「旅‧心活」旅居體驗計劃，讓港人以嶄新的旅居方式，盡情探索第二人生。（左至右）中銀人壽市場及產品發展總監魏志煒先生、中銀香港個人數字金融產品部總經理周國昌先生、中銀人壽執行總裁鄧子平先生、中銀信用卡（國際）總經理何偉文先生、中銀香港個人金融及財富管理部副總經理溫晞文女士。中銀人壽「旅․心活」會員尊享內地旅居基地禮遇和「六養合一」新體驗「旅․心活」提供糅合健康養生與旅行居住的全新體驗，擁有三大亮點，包括提供內地18個宜居城市作為旅居基地，讓會員按照喜好及不同季節選擇合適居住地；以「六養合一」理念，關注膳食、居住環境、醫療及社交等需求，締造身心靈滿足；專屬旅居管家提供一對一諮詢及禮賓服務，更會提供突發情況處理支援。中銀人壽特選客戶成功登記成為「旅․心活」會員後，即可尊享嶄新旅居禮遇。1.強勢佈局：中銀人壽依託中國銀行和中銀香港的强大資源，夥拍不同戰略合作夥伴建立強大旅居網絡，精心挑選內地18大旅居基地，涵蓋杭州、成都、青島、南京、福州、長沙、大理、三亞、黃山及珠海等及其他8個大灣區宜居城市，讓「旅․心活」會員在不同季節選擇最適合的旅居地，開啓探索第二人生。2.六養合一：以「六養合一」為理念，包括食養（專業健康膳食方案）、住養（高端酒店式康養居住環境）、醫養（養生設施及專業醫療康養服務）、動養（人性化生活設施配套及多元化康體活動課程）、旅養（一對一免費諮詢及禮賓服務以滿足休閒觀光及深度旅遊需求）、誼養（建立養老社區促進交際），全方位締造身心靈滿足。3.專屬旅居管家 尊貴配套：專屬旅居管家提供一對一諮詢及禮賓服務，由前期的旅居行程設計、行程資源代訂，入住期間的景點美食推薦，以及突發情況處理支援，專屬旅居管家均能線上線下全方位支援。運用「銀行＋保險」優勢，結合非金融服務，攜手打造優質退休生活中銀人壽致力發揮「銀行＋保險」的獨特優勢，為客戶退休後的旅居新模式提供多面向全體驗，包括夥拍中銀香港推出多元化現金流產品，如「月悅出息終身享保險計劃」、「中銀人壽延期年金計劃（終身）」等，實現理想退休生活。現凡投保「月悅出息終身享保險計劃」[2]即可成為中銀人壽特選客戶，可登記成為「旅․心活」會員，享受品味生活的尊貴禮遇，更有機會獲免費旅居套餐[3]，感受卓爾不凡的獨特旅居體驗。「旅‧心活」坐擁三大亮點，冀為客戶帶來「旅居養⽣」非凡新體驗，實現理想退休生活。中銀人壽未來將透過銀行與保險的聯動，讓客戶建立退休所需的財務保障，打造全方位的無憂退休方案。（左至右）藝人嘉賓黎彼得先生、中銀信用卡助理總經理（信用卡業務）關文萱女士、中銀香港個人金融及財富管理部副總經理溫晞文女士、中銀人壽市場及產品發展總監魏志煒先生、中銀香港個人數字金融產品部助理總經理李健興先生及藝人嘉賓孫慧雪女士。此外，為了協助港人無縫接軌內地消費模式，中銀香港的中銀銀聯雙幣卡及BoC Pay 電子錢包針對內地支付亦有一系列配套及專屬優惠，推動客戶於「旅․心活」18大旅居基地輕鬆享受無憂一站式跨境支付體驗。同時，為協助港人實現不同的人生目標，「旅․心活」將進一步開放至中銀香港「私人財富」客戶，鼓勵高端客戶以嶄新的旅居方式，打造愜意的優質退休生活，同時把財富代代相傳。 中銀人壽執行總裁鄧子平表示：「中銀人壽與中銀香港將加強協同，充分運用『銀行＋保險』優勢，依託總行全球化及綜合化資源，繼續發揮領航者角色，與全球知名康養企業合作，共同建立『綜合金融產品+多元養老服務』之養老金融服務方案，為客戶締造高品質的退休生活，滿足市場龐大需求，積極推動銀髮經濟發展，也為緩解香港高齡化社會問題貢獻力量。」 中銀人壽市場及產品發展總監魏志煒表示：「隨著人口結構轉變，人口老化成為全球各地及香港關注議題。中銀人壽早前首推『旅․心活』試點計劃，邀請100位特選客戶體驗旅居，獲得高度正面回饋，展示旅居市場的巨大潛力。退休並不是終點，而是享受生活的起點－我們冀藉著推出全新會員計劃，讓更多港人認識『旅居退休』新模式，為他們的退休生活提供更多選擇，呈獻不一樣的非金融體驗。」中銀人壽舉辦「2024旅居生活巡禮」 沉浸式體驗旅居魅力為全面推廣旅居概念，中銀人壽舉辦「2024旅居生活巡禮」，透過沉浸式體驗及精選特色活動，讓參與者深入感受旅居城市的魅力及「六養合一」文化。中銀人壽亦宣佈冠名贊助HOY TV黃金時段節目——《中銀人壽「旅․心活」旅居體驗計劃特約：退休旅居新模式》，希望協助港人輕鬆具體化退休後的理想旅居生活，並提早規劃相對應的財務藍圖，發掘精彩第二人生。[1]更多中銀人壽「旅․心活」旅居體驗計劃詳情，請參閱：https://www.boclife.com.hk/tc/retirecation/home.html [2]更多「月悅出息終身享保險計劃」計劃詳情，請參閱中銀人壽公司網頁以瀏覽產品小冊子：https://www.boclife.com.hk/tc/product/incomejoy-lifelong-insurance-plan.html [3]成功投保中銀人壽指定保險產品，且符合指定保費要求，有機會尊享免費旅居體驗套餐一次及專屬旅居管家服務。優惠受條款及細則約束，詳情請參閱：https://www.boclife.com.hk/tc/promotion/incomejoy-lifelong-insurance-plan-retirecation-reward.html Copyright 2024 亞太商訊 via SeaPRwire.com.